Skip to main content
Clinical Trials/JPRN-UMIN000033511
JPRN-UMIN000033511
Completed
未知

Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetes - Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp

Yokohama City University Medical Center Department of Endocrinology and Diabetes0 sites60 target enrollmentJuly 26, 2018
ConditionsType2 diabetes

Overview

Phase
未知
Intervention
Not specified
Conditions
Type2 diabetes
Sponsor
Yokohama City University Medical Center Department of Endocrinology and Diabetes
Enrollment
60
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 26, 2018
End Date
December 31, 2019
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Yokohama City University Medical Center Department of Endocrinology and Diabetes

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Patients with severe renal dysfunction including patients requiring hemodialysis or peritoneal dialysis(eGFR\<30ml/min). 2\)pregnant 3\)Patients who have severe diabetic ketosis, diabetic coma. 4\)Patients with severe infection, severe injury or perioperative state.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes.Diabetes Mellitus, Type 2MedDRA version: 19.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-002605-29-SEovo Nordisk A/S94
Active, not recruiting
Phase 1
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes.Diabetes Mellitus, Type 2MedDRA version: 20.0 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000072461Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-002605-29-GBovo Nordisk A/S135
Active, not recruiting
Phase 3
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetesHealth Condition 1: null- Diabetes Mellitus, Type 2Health Condition 2: E11- Type 2 diabetes mellitus
CTRI/2013/10/004082ovo Nordisk AS
Active, not recruiting
Phase 1
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes.Diabetes Mellitus, Type 2MedDRA version: 18.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-002605-29-ATovo Nordisk A/S150
Active, not recruiting
Phase 1
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes.Diabetes Mellitus, Type 2MedDRA version: 19.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-002605-29-NLovo Nordisk A/S150